Sen. Pryor's S 2000
"Part of the Pryor bill could very well be wrapped into" a comprehensive health care reform package, Senate Budget Committee Chairman Sasser (Tenn.) predicts at a Feb. 19 National Health Council breakfast. Sasser expresses support for the Pryor bill, which would reduce Sec. 936 tax credits for pharmaceutical companies if product prices increase faster than inflation and also would direct HHS to study the feasibility of a drug price review board similar to one in Canada.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth